Eczema (Atopic Dermatitis)
Eczema (Atopic Dermatitis)
MEDI-MM36-302 Enrolling

Atopic Dermatitis – Research Trial (52 Weeks)

Treatment: Topical Age: 2 or older

Children, adolescents, and adults aged aged 2 years or older who have mild to moderate atopic dermatitis (AD), persistent for more than 3 months, may be eligible for a 52-week research trial. Eligible participants having mild to moderate atopic dermatitis, with a diagnosis of AD for at least 3 months prior to screening, and no active or acute skin infections.

Participants will receive investigational topical treatment (active study drug) or placebo (inactive substance), via a cream.  Study treatment and study-related assessments will be provided at no cost.  Reimbursement for study-related expenses will be provided.

Study participation will last about 52 weeks and involve about 15 visits to the study centre.

Participating Locations

United States

Participating Experts

Dr. Victoria Farley


Dr. Brandon Kirsch


Dr. Matthew Zirwas


You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from

Last Update Posted: November 25, 2022

Study Description

  • Ages Eligible for Study:

    2 years and older

  • Sexes Eligible for Study:

    Male and Female

Terms and Conditions –
Purpose of Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed to provide patients, family members, and members of the public current information about clinical research studies.


Learn More About

Eczema (Atopic Dermatitis)

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content